Skip to main content

Web Exclusives

FDA Updates

Rozlytrek Third FDA-Approved Tumor-Agnostic Drug and Second Treatment for Patients with NTRK Fusion Tumors

Meeting Highlights

Breast Cancer, ESMO Highlights, CDK4/6 Inhibitors

Adding CDK4/6 Inhibitor to Endocrine Therapy Improves Survival in Advanced Breast Cancer: New Standard of Care

Head and Neck Cancer

Oral Cancer and Sex in the Era of HPV Infection

Meg Barbor, MPH

Ovarian Cancer, FDA Updates

October 28, 2019 – Oncology News & Updates

Breast Cancer, Multiple Myeloma, Pediatric Cancer, FDA Updates

Vincristine, Racial Disparities in Multiple Myeloma, and HER2 Metastatic Breast Cancer Are in the News

FDA Updates

FDA on In Vitro Diagnostics, Vaping; Cost of Novel Treatments

Multiple Myeloma, FDA Updates

FDA Approves Darzalex Combination for First-Line Treatment of Transplant-Eligible Patients with Multiple Myeloma

Renal-Cell Carcinoma

Avelumab plus Axitinib New First-Line Standard of Care in Advanced Renal-Cell Carcinoma

Lymphoma, FDA Updates

Polivy FDA Approved for Patients with Relapsed or Refractory DLBCL

Multiple Myeloma

Economic Implications of Inpatient versus Outpatient Autologous Transplant for Patients with Multiple Myeloma

Page 24 of 43
Results 231 - 240 of 428